Immunohistochemical evidence of ubiquitous distribution of the metalloprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cells is presented. Immunohistochemical staining was performed on a multi-organ tissue microarray (pancreas, lung, kidney, central/peripheral nervous system, liver, breast, placenta, myocardium, striated muscle, bone marrow, thymus, and spleen) and on a cell microarray of 31 tumor cell lines of different origin, as well as trophoblast cells and normal blood lymphocytes and granulocytes. IDE protein was expressed in all the tissues assessed and all the tumor cell lines except for Raji and HL-60. Trophoblast cells and granulocytes, but not normal lymphocytes, were also IDE-positive.
-dependent metalloendopeptidase insulin-degrading enzyme (IDE, insulysin, insulinase; EC 3.4.22 .11, molecular mass 110 kDa) belonging to the M16A pitrilysin subfamily, although protein disulfide isomerase and cathepsin D are also involved in insulin metabolism (Duckworth et al., 1998; Valera Mora et al., 2003; Barrett and Rawlings, 2004) . Increased expression of IDE is correlated with decreased circulating levels of insulin and Ab peptide, whereas IDE deficiency is correlated with increased risk of Alzheimer's disease and type 2 diabetes mellitus (Bertram et al., 2000; Bennett et al., 2003; Sladek et al., 2007) .
Although insulin clearance predominantly occurs in the liver and the kidney, other tissues and cell types may also participate in insulin degradation, especially striated muscle, adipocytes, gastrointestinal epithelia, fibroblasts, monocytes and lymphocytes (Valera Mora et al., 2003) . Apart from insulin, other growth factors were also found to be substrates for IDE, such as transforming growth factor a (Gehm and Rosner, 1991) , indicating that IDE has potential as a ubiquitous degrader of growth factors.
IDE is ubiquitously expressed (www.genecards.org/ cgi-bin/carddisp.pl?genesIDE) and is present in bacteria, fungi, plants, animals, and humans (Kuo et al., 1993; Adames et al., 1995; Becker and Roth, 1995; Bertram et al., 2000; Bennett et al., 2003; Sladek et al., 2007 ; see also the distribution within family M16.002: insulysin at http://merops.sanger.ac.uk/). Kuo et al. (1993) investigated IDE distribution in rat tissues at the gene and protein levels; expression was demonstrated in the testis, tongue, brain, kidney, prostate, heart, muscle, liver, intestine, skin, spleen, lung, thymus, and uterus. However, less is known about the distribution of IDE protein in human tissues, although it has been detected in liver, adipocytes (Valera Mora et al., 2003) , muscle cells (Neal and Kitabchi, 1982) , erythrocytes (Shii et al., 1986) , breast and kidney (Duckworth et al., 1998; Radulescu et al., 2007) .
Besides its predominant presence in the cytosol (Authier et al., 1996; Chang et al., 1997) , IDE is also found in small but significant amounts in subcellular compartments of cultured cells, e.g., on the plasma membrane (Hersh, 2006) , in endosomes (Hamel et al., 1991) , peroxisomes (Authier et al., 1995) , and mitochondria (Leissring et al., 2004) . So far, human IDE expression and function have been studied mainly in the context of diabetes mellitus and Alzheimer's disease (Farris et al., 2005) , but not yet with respect to cancer, except for some reports on IDE presence in tumor cell lines (Harada et al., 1993; Authier et al., 1996; Melino et al., 1996; Chang et al., 1997) .
We recently explored protein expression of IDE in human normal and neoplastic breast tissues by immunohistochemistry for the first time (Radulescu et al., Figure 1 Immunohistochemical analysis of normal human tissues using rabbit polyclonal antibody UCG 43/6 directed against recombinant full-length IDE (Shen et al., 2006) . IDE staining in red; nuclei were counterstained with hematoxylin (blue). Original microscopic magnification, 400=. Staining intensity: (A) liver, strong immunoreactivity (3q) present in hepatocytes; (B) kidney, strong immunoreactivity (3q) present in tubular cells surrounding a negative glomerulum (0) Tissue microarrays were constructed using a 1-mm punch-core needle instrument (MTA I Personal Tissue Arrayer, Beecher Instruments, Sun Prairie, USA) as previously described (Simon et al., 2003) . To compensate for individual differences in tissue heterogeneity and staining intensity, specimens from three different individuals were sampled per organ. Tissue microarrays were deparaffinized and hydrated by passing them through xylene and a graded ethanol series. Antigen retrieval was performed by boiling the slides in 10 mM citrate buffer, pH 6.0 for 4 min. Endogenous peroxidase activity was quenched by incubating the sections with 3% H 2 O 2 in distilled H 2 O for 20 min at room temperature (RT). Sections were incubated overnight at 48C with 5 ml of rabbit polyclonal antibody UCG 43/6 against recombinant full-length human IDE (Shen et al., 2006) per ml of antibody diluent S2022 (Dako, Hamburg, Germany), washed with TBS and then peroxidase-labeled mouse-anti-rabbit IgG (Jackson Immunoresearch, Dianova, Hamburg, Germany) was added (30 min, RT). Control tissue microarrays contained no primary antibody. Sections were then washed with TBS, followed by addition of the peroxidase substrate 3-amino-9-ethylcarbazole (K3464, Dako). Stained sections were photographed using a Sony 3CCD color video camera attached to a Zeiss (Gö ttingen, Germany) Axioplan 2 microscope using Zeiss AxioVision software 4.5 SP1. A four-grade scoring system was used to assess the intensity of immunoreactivity: 0, negative; 1q, weak; 2q, moderate; and 3q, strong. Punch core biopsies of normal human kidney known to express IDE protein (Su et al., 2004) were used as an internal positive control; for negative controls the primary antibody was omitted.
Figure 2
Immunohistochemical analysis of normal human tissues using rabbit polyclonal antibody UCG 43/6 directed against full-length IDE. IDE staining in red; nuclei were counterstained with hematoxylin (blue). Original microscopic magnification, 400=. Staining intensity: (A) breast, moderate but heterogeneous immunoreactivity (2q) present in duct epithelia of the mammary gland; (B) placenta, moderate but heterogeneous immunoreactivity (2q) present in trophoblast cells; (C) bone marrow, strong staining (3q) present in hematopoietic cells; and (D) thymus, weak staining (1q) present in lymphocytes and epithelial cells.
2007) and reported that IDE expression is elevated in human breast cancer tissues compared to normal breast glands. Furthermore, using an immunoassay we detected insulin protein in high-grade breast cancer, a result that is in line with early findings by other groups (Castro et al., 1980; Spring-Mills et al., 1984) . To better understand whether IDE acts as a local or a global player in human tissues, we assessed IDE protein expression patterns in normal human cells and tissues and in cultured tumor cells using the IDE-directed antibody UCG 43/6. This polyclonal antibody was generated by injecting rabbits with recombinant human wild-type IDE tagged with six histidine residues at the N-terminus, as outlined by Chesneau and Rosner (2000) and Shen et al. (2006) . The antibody was applied to normal tissues, normal cells and tumor cells. For this purpose, tissue microarrays and cell microarrays were prepared encompassing 13 normal tissues (Table 1, Figures 1-3) , several normal cells and 31 tumor cell lines (Table 2 , Figures  4-6) .
IDE was detected in the cytoplasm of a wide range of cells within the 13 normal human tissues investigated (Table 1, Figures 1-3 ), in agreement with findings published for rat IDE by Kuo et al. (1993) . For instance, All cell lines were cultivated in DMEM supplemented with 10% fetal calf serum, 0.2% arginine/asparagine and 1% HEPES or RPMI supplemented with 10% fetal calf serum and 1% glutamine. For construction of cell microarrays, cultured cells (3=10   7   ) were fixed with 5 ml of 10% formalin in phosphate-buffered saline (PBS) for 30 min at 208C, centrifuged (800 g, 5 min, 208C), washed with Trisbuffered saline at 208C, then with PBS, and centrifuged again. Subsequently, 150 ml of thrombin (10 U/ml in H 2 O; Sigma-Aldrich, Munich, Germany), 750 ml of casein (Sigma-Aldrich; 10 mg/ml in 0.04 M Tris-HCl, pH 8.0) and 600 ml of fibrinogen (25 mg/ml H 2 O; Sigma-Aldrich) were added to the cell pellet and left overnight at 48C to solidify. Cell clots were fixed in 4% formalin in PBS, embedded, and paraffinized according to standard procedures. Since cells were formalin-fixed and paraffin-embedded, the procedure for construction of cell microarrays was identical to that for tissue microarrays (see the legend to Table 1 ). Cell microarrays were stained for IDE protein expression using polyclonal rabbit antibody UCG 43/6 and a streptavidin-biotin detection kit (LSAB, K5003; Dako) as described by Radulescu et al. (2007) . Punch cores of a cell clot of the colon cancer cell line Caco-2 known to express IDE protein (Chang et al., 1997) were used as an internal positive control; for negative controls the primary antibody was omitted. a TUM, Department of Obstetrics and Gynecology, Technical University of Munich. moderate to strong cytoplasmic expression of IDE was observed in hepatocytes and renal tubule cells, whereas glomeruli did not immunostain with the IDE-directed antibody. This is not surprising, since both organs exhibit high insulin degradation rates (Valera Mora et al., 2003) . Although IDE was distributed homogeneously within cells in most of the tissues investigated, striated muscle and cardiomyocytes displayed intense cytoplasmic but subcellular compartmentalization of IDE expression ( Figure  3) . In this context it is worth mentioning that insulin can be cleared by muscle cells, which contain insulin receptors and a regulation mechanism for insulin internalization and metabolism (Valera Mora et al., 2003) .
The tissue-wide distribution of IDE protein observed points to the fact that a wide range of tissues may be capable of insulin uptake and degradation, which highlights the essential metabolic role of insulin and its control by insulin-degrading enzymes such as IDE (Hamel et al., 1991; Fawcett et al., 2007) . Against the background of ubiquitous IDE expression in normal tissues and cells, it is not surprising that 29 of the 31 human tumor cell lines tested exhibited some degree of cytosolic IDE protein expression (Table 2 , Figures 4-6), whereas Raji lymphoma cells and HL-60 leukemia cells did not immunostain with the IDE-directed antibody. Peripheral blood lymphocytes were also negative. In addition, we confirmed the findings of Chang et al. (1997) , who reported expression of IDE protein by the colon cancer cell line Caco-2. Interestingly, the breast cancer cell lines investigated showed moderate to strong IDE expression, a finding linked to results obtained by immunostaining of high-grade breast cancer specimens for the presence of IDE protein (Radulescu et al., 2007) .
Since insulin is widespread in the human organism, binding to receptors on almost every cell type, it is not surprising that IDE, the most important enzyme in insulin Figure 3 Immunohistochemical analysis of normal human tissues using rabbit polyclonal antibody UCG 43/6 directed to fulllength IDE. IDE staining in red; nuclei were counterstained with hematoxylin (blue). Original microscopic magnification, 400=. Staining intensity: (A) striated muscle, weak immunoreactivity (1q); (B) cardiomyocytes of the heart, moderate immunoreactivity (2q); (C) nerve ganglions of the peripheral nervous system, moderate immunoreactivity (2q); and (D) peripheral blood granulocytes, moderate immunoreactivity (2q). metabolism and an important degrader of other small proteins, was detected in almost all tissues and cell types, in agreement with IDE RNA expression data reported by Su et al. (2004) as part of the gene atlas (symatlas) of the human transcriptome.
Clinical and epidemiological studies have shown that type 2 diabetes and hyperinsulinemia increase the risk of developing Alzheimer's disease in the elderly. The link between hyperinsulinemia and Alzheimer's disease may be IDE (Qiu and Folstein, 2006) . Besides insulin, IDE also degrades amylin, a peptide related to the pathology of type 2 diabetes, along with amyloid-b peptide, which is found in the brain of Alzheimer patients (Qiu and Folstein, 2006) . Furthermore, functional in vitro studies have shown that IDE and insulin are key regulators of the proteasome, a ubiquitous protein complex that degrades unnecessary and damaged proteins by proteolysis. In this respect, loss of lean muscle mass in insulin-dependent diabetes mellitus is a result of accelerated proteolysis by the proteasome, since insulin inhibits protein degradation by interaction with IDE (Bennett et al., 2003; Fawcett et al., 2007) . The regulation of IDE expression is not fully elucidated, but ATP seems to act as a negative regulator of IDE (Camberos et al. 2001) . Although studies of the role of IDE in the pathogenesis of diabetes mellitus and Alzheimer's disease are the focus of ongoing clinical research, such studies have not reported on the role of IDE in malignancy yet.
